Chemours (NYSE:CC) Insider Calderon Gerardo Familiar Buys 1,935 Shares of Stock

Key Points

• Insider purchase: Chemours insider Calderon Gerardo Familiar bought 1,935 shares at an average price of $15.53, increasing direct ownership by 3.42% to 58,547 shares.
• Weak quarterly results: Chemours reported quarterly EPS of $0.42, below the $0.49 analyst consensus, while revenue of $1.59 billion declined 1.5% year over year.
• Stock and dividend update: Shares traded near $15.23, well below the average analyst target of $20.10. The company declared a quarterly dividend of $0.0875 per share, equivalent to a 2.3% annualized yield.

The Chemours Company (NYSE:CC - Get Free Report) insider Calderon Gerardo Familiar purchased 1,935 shares of the firm's stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This represents a 3.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Chemours Stock Down 0.1%

Shares of NYSE CC traded down $0.01 during midday trading on Thursday, reaching $15.23. The company's stock had a trading volume of 3,639,033 shares, compared to its average volume of 3,109,865. The Chemours Company has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The stock has a 50 day simple moving average of $18.76 and a 200-day simple moving average of $20.03. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -7.97 and a beta of 1.43. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period last year, the business posted ($2.54) EPS. The firm's revenue for the quarter was down 1.5% on a year-over-year basis. Equities research analysts predict that The Chemours Company will post 0.88 earnings per share for the current year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th will be issued a $0.0875 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's dividend payout ratio (DPR) is presently -18.32%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CC. Morgan Stanley set a $18.00 price target on Chemours in a research report on Monday. Alembic Global Advisors reissued an "overweight" rating and issued a $30.00 price objective on shares of Chemours in a report on Wednesday, May 13th. BMO Capital Markets lowered their target price on shares of Chemours from $26.00 to $18.00 and set an "outperform" rating on the stock in a report on Thursday. Royal Bank Of Canada cut their price target on shares of Chemours from $26.00 to $22.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings lowered shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Chemours currently has an average rating of "Hold" and an average target price of $20.10.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Sanctuary Advisors LLC bought a new stake in Chemours in the 2nd quarter valued at $323,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Chemours in the second quarter valued at $18,119,000. Pinnacle Holdings LLC acquired a new position in shares of Chemours in the second quarter valued at $1,628,000. Haverford Trust Co bought a new position in shares of Chemours in the second quarter valued at about $552,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Chemours in the second quarter valued at about $296,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source